Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also ...

based medical technology company Hologic Inc. over concerns it hasn't done enough to prevent harm from a plastic component in the company's Biozorb implantable radiographic markers. Hologic's ...

During an inspection from July 30 to Sept. 24, 2024, at Hologic’s Marlborough, Massachusetts, facility, the FDA identified several deficiencies related to the production of BioZorb, a class II ...

Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close. In the first quarter of fiscal 2025, HOLX is expected to have benefited from the ...

Hologic (HOLX) closed at $71.19 in the latest trading session, marking a +1.17% move from the prior day. This change outpaced the S&P 500's 0.61% gain on the day. Meanwhile, the Dow gained 0.3% ...

Piero Cingari FDA Warns Hologic Over BioZorb Manufacturing Violations FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and ...